Figure 5.

Correlation between CK20 positivity in bone marrow samples and survival for patients with esophageal carcinoma who had not received neo-adjuvant chemotherapy. CK20 positivity in bone marrow of EC patients who had not received neo-adjuvant chemotherapy (n = 12) was assessed by RT-PCR and correlated with (A) overall survival and (B) tumor-specific survival. The p-values for the comparison of the cumulative survival probabilities of the two groups (CK20-positive versus CK20-negative) were calculated using the log-rank test. On the vertical dotted line at 60 months, the percentages of 5-year overall survival are shown in brackets. On the horizontal dotted line at the cumulative survival probability of 0.5 is the median survival and is given in months in square brackets.